Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults aged 65 and above with a single shot of the respiratory syncytial virus (RSV) vaccine from Pfizer or GSK may significantly reduce hospitalizations during two seasons of the virus, according to an analysis conducted by researchers at the University of Michigan …
A healthcare professional in Los Angeles prepares a flu vaccine shot for a local resident. Xinhua News Agency | Getty Images A committee advising the Centers for Disease Control and Prevention (CDC) has recommended that adults aged 60 and above consult their doctors and receive a single dose of RSV vaccines from Pfizer and GSK. …
A Potential Breakthrough: Pfizer’s Ongoing Research on Respiratory Syncytial Virus Vaccines Image Source: Hailshadow | Istock | Getty Images Pfizer reported a slight decrease in the efficacy of their respiratory syncytial virus (RSV) vaccine for adults over the age of 60 after 18 months, based on the results of a recent clinical trial. The trial, …
Exciting Advances in Respiratory Syncytial Virus Vaccine Research Image Source: Hailshadow | Istock | Getty Images – GlaxoSmithKline announced today that their respiratory syncytial virus (RSV) vaccine for adults aged 60 and older has proven effective over two RSV seasons. According to recent data from a phase three clinical trial, a single dose of the …
In a noteworthy development, the U.S. Food and Drug Administration (FDA) has selected Pfizer, Moderna, and Novavax as the manufacturers for the next round of COVID-19 booster shots. This decision sets the stage for a competitive race among the vaccine makers as they strive to deliver their new jabs by fall. The FDA has advised …
A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S. Food and Drug Administration’s independent panel of advisors on Thursday recommended updating Covid shots for the fall and winter to target one specific variant – the …
In this illustration photo taken in Krakow, Poland on December 2, 2021, medical syringes and the Novavax logo are prominently displayed in the background. Novavax, a cash-strapped Covid vaccine maker, is confident about its ability to survive and thrive. The Maryland-based company recently announced its first-quarter financial results, which included a cost-cutting initiative and a …